Link between biological aging and type 2 diabetes risk in people with liver disease
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study
This study looks at how biological aging might affect the risk of developing type 2 diabetes in people with liver disease and those without it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2720 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Ningbo No. 1 Hospital Academic / other |
| Locations | 1 site (Ningbo, Zhejiang) |
| Trial ID | NCT06984510 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between biological aging and the incidence of type 2 diabetes mellitus (T2DM) in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will assess biological age using various methods, including phenotypic age and homeostatic dysregulation, and will employ statistical models to analyze the association between biological aging and T2DM risk. The study aims to clarify how biological aging may influence the development of T2DM in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with available abdominal ultrasound data and at least one recorded metabolic indicator.
Not a fit: Patients under 20 or over 90 years old, those with existing type 2 diabetes, or those with other causes of liver disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of biological aging in the risk of developing type 2 diabetes, potentially leading to better prevention strategies.
How similar studies have performed: While the specific approach of this study may be novel, other studies have explored the relationship between biological aging and diabetes risk, indicating potential for meaningful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Abdominal ultrasound data available in annual health check-up records 2. At least one of the following five metabolic indicators recorded annually: (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c) Exclusion Criteria: 1. Age \<20 or \>90 years 2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection) 3. Type 2 diabetes mellitus at baseline 4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Where this trial is running
Ningbo, Zhejiang
- the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000 — Ningbo, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Lei Xu
- Email: xulei22@163.com
- Phone: +8613486659126
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.